Partner Case Study

TEVA supports National Cancer Coalition International Relief Program

Named Individuals:
Robert B. Landry
Joe Cunliffe
Jeff Borden

TEVA Pharmaceuticals USA and the National Cancer Coalition have partnered for the past decade to assist underserved patients in gaining access to the medicines that they require.  During this timeframe, NCC has received and then provided to our overseas partner hospitals over $75 million dollars worth of chemotherapy and adjunctive therapies from TEVA.  This generosity has enabled many thousands of patients to receive treatment for their cancers.

In addition to is world class oral formulations of Rx medicines manufactured in Pennsylvania, the TEVA Injectables division, based in Irvine CA, is one of the largest and most sophisticated manufacturers of a vast line of cancer injectable medicines which are used to treat many types of cancer, which include breast cancer, cervical cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, solid tumors, and many others.  For the past decade, NCC has been a preferred partner of TEVA and regularly receives donations of its high quality cancer, specialty and essential medicines. 

This important partnership has allowed treatment opportunities for countless cancer patients in the developing world, enabling over 300,000 patient months of cancer therapy to individual patients in need.  TEVA is the largest generic pharmaceutical company in the world and it ranks in the Top 20 globally; it also manufactures a whole range of chronic disease and essential medicines in which they partner with NCC to provide these to our partners in the developing world.

NCC President Robert B. Landry stated, “TEVA is an exceptional company that manufactures a broad portfolio of high quality products for cancer and other serious illnesses.  The National Cancer Coalition is proud to be a preferred NGO partner of TEVA and this partnership has allowed the overseas public cancer hospitals that we assist in the developing world access to first class cancer therapies.”  Landry added, “Utilizing NCC’s vast overseas network, the TEVA medicines have enabled countless patients to receive treatment for their cancer and to have the opportunity for survival.”

About TEVA

Teva Pharmaceuticals USA is the leading generic pharmaceutical company, marketing products from a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatology, respiratory, and women's health. Dosage forms include tablets and capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. Teva USA products are marketed to chains, wholesalers, distributors, and government agencies, as well as in health systems and oncology settings. Teva USA has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry. The company's mission is to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture, and marketing of generic pharmaceuticals. Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., the leader in generic pharmaceuticals, and among the top 20 pharmaceutical companies in the world.

Website: http://www.tevausa.com/

Physical Locations:

Paraguay
Pennsylvania
Irvine
California

Specific Brand Names

TEVA

NCC Campaigns

NCC Cares
SMART Program

NCC Cares - Paraguay - Teva - USA